| Name | Title | Contact Details |
|---|
Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.
ERT is a global company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.
Compass Health Northwest Washington’s Behavioral Healthcare Leader Access Services Compass Health provides comprehensive services to treat behavioral health…
Qualyst is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Impel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimers, migraine, and other central nervous system diseases.